MXPA03009259A - Polimorfos de clorhidrato de fexofenadina. - Google Patents

Polimorfos de clorhidrato de fexofenadina.

Info

Publication number
MXPA03009259A
MXPA03009259A MXPA03009259A MXPA03009259A MXPA03009259A MX PA03009259 A MXPA03009259 A MX PA03009259A MX PA03009259 A MXPA03009259 A MX PA03009259A MX PA03009259 A MXPA03009259 A MX PA03009259A MX PA03009259 A MXPA03009259 A MX PA03009259A
Authority
MX
Mexico
Prior art keywords
forms
fexofenadine hydrochloride
preparation
polymorphs
present
Prior art date
Application number
MXPA03009259A
Other languages
English (en)
Inventor
Dolitzky Ben-Zion
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA03009259A publication Critical patent/MXPA03009259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente .invencion provee formas de cristales nuevas de las Formas (V, VI y VIII a XV) de clorhidrato de fexofenadina y procesos para su preparacion y la preparacion de la forma amorfa y de otras formas cristalinas del clorhidrato de fexofenadina. Las Formas (XIV y XV) son solvatos de acetato de etilo. La Forma IX es anhidra, pero se puede cristalizar como un solvato de MTBE o ciclohexano. Las formas son utiles para la administracion a humanos y animales para aliviar sintomas causados por la histamina. La presente invencion ademas provee composiciones farmaceuticas de las nuevas formas cristalinas.
MXPA03009259A 2001-04-09 2002-04-08 Polimorfos de clorhidrato de fexofenadina. MXPA03009259A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28252101P 2001-04-09 2001-04-09
US30775201P 2001-07-25 2001-07-25
US31439601P 2001-08-23 2001-08-23
US33693001P 2001-11-08 2001-11-08
US33904101P 2001-12-07 2001-12-07
US34411401P 2001-12-28 2001-12-28
US36178002P 2002-03-04 2002-03-04
US36348202P 2002-03-11 2002-03-11
PCT/US2002/011251 WO2002080857A2 (en) 2001-04-09 2002-04-08 Polymorphs of fexofenadine hydrochloride

Publications (1)

Publication Number Publication Date
MXPA03009259A true MXPA03009259A (es) 2004-06-03

Family

ID=27575329

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009259A MXPA03009259A (es) 2001-04-09 2002-04-08 Polimorfos de clorhidrato de fexofenadina.

Country Status (13)

Country Link
US (3) US20020177608A1 (es)
EP (1) EP1392303A4 (es)
KR (1) KR20040012747A (es)
AU (1) AU2002305162A1 (es)
CA (1) CA2444456A1 (es)
CZ (1) CZ20033019A3 (es)
HR (1) HRP20030900A2 (es)
HU (1) HUP0400299A2 (es)
IL (1) IL158334A0 (es)
MX (1) MXPA03009259A (es)
PL (1) PL366576A1 (es)
SK (1) SK13822003A3 (es)
WO (1) WO2002080857A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
DE60220953T2 (de) 2002-04-04 2008-02-28 Dr. Reddy's Laboratories Ltd. Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
ES2239554T1 (es) 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. Forma xvi polimorfica de hidrocloruro de fexofenadina.
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
CA2560882A1 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
WO2006037042A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
JP2009543780A (ja) * 2006-07-11 2009-12-10 ミューチュアル ファーマシューティカル カンパニー，インク． 制御放出製剤およびキット
US20090306135A1 (en) * 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
WO2009136412A2 (en) * 2008-04-25 2009-11-12 Matrix Laboratories Limited PROCESS FOR PREPARATION OF 4-[4-(4-(HYDROXYDIPHENYLMETHYL)- 1-PIPERIDINYL]-1-OXOBUTYL]-α,α-DIMETHYLBENZENE ACETIC ACID METHYL ESTER AND USE THEREOF
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
ES2403130B1 (es) * 2010-06-15 2014-09-29 Chemelectiva S.R.L. Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
HU194864B (en) * 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
AU671822B2 (en) * 1992-04-10 1996-09-12 Aventisub Ii Inc. 4-diphenylmethyl piperidine derivatives and process for their preparation
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
WO1993023047A1 (en) * 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
ATE322899T1 (de) * 1992-08-03 2006-04-15 Sepracor Inc Terfenadin-carboxylat und die behandlung von allergischen erkrankungen
US5654433A (en) * 1993-01-26 1997-08-05 Merrell Pharmaceuticals Inc. Process for piperidine derivatives
DE69433346T2 (de) * 1993-06-24 2004-09-09 Albany Molecular Research, Inc. Herstellung von Verbindungen, die in der Produktion von Piperidin-Derivaten nützlich sind
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
AU699559B2 (en) * 1993-06-25 1998-12-10 Aventisub Ii Inc. Novel intermediates for the preparation of antihistaminic piperidine derivatives
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) * 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
ES2216191T3 (es) * 1997-03-11 2004-10-16 Aventis Pharmaceuticals Inc. Procedimiento para preparar acido 4-(4-(hidroxidifenil)-1-piperidinil)-1-hidroxibutil)-alfa,alfa-dimetilfenilacetico y derivados fosforilados.
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
KR100514264B1 (ko) * 1997-08-26 2005-09-15 아벤티스 파마슈티칼스 인크. 피페리디노알칸올-충혈완화제 조합용 제약 조성물
US5885912A (en) * 1997-10-08 1999-03-23 Bumbarger; Thomas H. Protective multi-layered liquid retaining composite
IN191492B (es) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
JP2004517699A (ja) * 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
EP2261209A1 (en) * 2001-06-18 2010-12-15 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of 4-[4-[4- hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenene acetic acid and its hydrochloride
ES2301662T3 (es) * 2001-07-31 2008-07-01 Texcontor Etablissement Polimorfo de clorhidrato de fexofenadina.
DE60220953T2 (de) * 2002-04-04 2008-02-28 Dr. Reddy's Laboratories Ltd. Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
ES2239554T1 (es) * 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. Forma xvi polimorfica de hidrocloruro de fexofenadina.
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
WO2005077884A2 (en) * 2004-02-10 2005-08-25 Union Carbide Chemicals & Plastics Technology Corporation Hydroaminomethylation of olefins
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant

Also Published As

Publication number Publication date
PL366576A1 (en) 2005-02-07
KR20040012747A (ko) 2004-02-11
EP1392303A4 (en) 2005-01-26
WO2002080857A3 (en) 2003-12-18
HUP0400299A2 (en) 2007-08-28
CA2444456A1 (en) 2002-10-17
CZ20033019A3 (cs) 2004-07-14
US20040058955A1 (en) 2004-03-25
WO2002080857A2 (en) 2002-10-17
AU2002305162A1 (en) 2002-10-21
IL158334A0 (en) 2004-05-12
HRP20030900A2 (en) 2005-08-31
SK13822003A3 (sk) 2004-09-08
EP1392303A2 (en) 2004-03-03
US20020177608A1 (en) 2002-11-28
WO2002080857A8 (en) 2004-05-27
US20090149497A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
MXPA03009259A (es) Polimorfos de clorhidrato de fexofenadina.
PL370381A1 (en) Substituted piperazines as modulators of the melanocortin receptor
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
CA2434277A1 (en) Substituted alkylamine derivatives and methods of use
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
WO2004007481A3 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders
NO331068B1 (no) Benzazepinderivater for behandling av nevrologiske forstyrrelser.
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
WO2003084937A3 (en) Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
IL172419A0 (en) Piperazine derivatives and methods of use
MXPA05010883A (es) Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina.
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
HUP0200580A2 (hu) Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
HUP0401141A2 (hu) A fluvasztatin-nátrium kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300370A2 (hu) Antimikrobiális hatású 2-hidroxi-mutilin-karbamát-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
NO20092413L (no) Pyrazolanaloger
WO2003039482A3 (en) Polymorphs of fexofenadine base

Legal Events

Date Code Title Description
FA Abandonment or withdrawal